MODIFIED PTO/SB/08 (08-00) Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Ander the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

number.		·				
	Substitute f	or form 1449B	/PTO		Complete If Known	2
	INFORMAT	ION DISCLO	SURE	Application Number	10/002,211	
	STATEMEN	IT BY APPLI	ICANT	Filing Date	12/05/2001	FEB 0 8 2004
				First Named Inventor	David M. GOLDENBERG	10
				Group Art Unit	3763	
	(use as many	sheets as ne	cessary)	Examiner Name	Unassigned CHUN CK	ON DE
Sheet	1	of	2	Attorney Docket Number	018733-1066	BADEM

				U.S. PATENT DOCUMENTS	3			
		U.S. Patent	Document		Date of Publication of	Pages, Columns, Lines, Where Relevant		
Examiner Initials*	Cite No. ¹	Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear		
	B1	4,036,945	A	HABER	07-19-1977	7		
	B2	4,331,647	А	GOLDENBERG	05-25-1982			
	вз	4,444,744	A	GOLDENBERG	04-24-1984	consideral		
	B4	4,735,210	A >>	GOLDENBERG	04-05-1988	817/06		
	B5	5,101,827	A	GOLDENBERG	04-07-1992			
	86	5,144,807	A	PFAHL	09-01-1992			
	BZ	5,152,980	A	STROM et al.	10-06-1992			

								-
				FC	DREIGN PATENT DOCUMEN	TS		
Examiner Initials*	Cite No.1	F Office	oreign Patent D	ocument Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
C.C.	B8	EP	0 217 992	A	BETH ISRAEL HOSPITAL	04-15-1987		
. C.C	B9	EP	0 274 394	A	ONCOGEN	07-13-1988	1 TOT CI	nd
	-B10	-EP	0 330 201		NEORX CORPORATION LTM	COAS	deres 12/0	5/0
<i>C</i> ,C .	B11	wo	83/04313	A	UNIV CALIFORNIA	12-08-1983		
<i>C. C.</i>	B12	wo	89/07601	A	TAN KIM SZE	08-24-1989		
C.	B13	wo	91/16069	Α	US HEALTH '	10-31-1991		
C.C.	B14	wo	93/13805	А	BAGSHAWE	07-22-1993		
C,C.	B15	wo	94/10202	A	GENENTECH INC.	05-11-1994	·	
						REST AVA	LABLE COF	Υ

Examiner Signature	a	of	Date Considered	02/28/07

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

MODIFIED PTO/SB/08 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

Substitute for	r form 1449B	/PTO	Complete if Known Application Number 10/002,211				
INFORMATIO	ON DISCLO	SURE					
STATEMENT	T BY APPL	ICANT	Filing Date	12/05/2001	APE.		
			First Named Inventor	David M. GOLDENBE		\sum_{i}	
•			Group Art Unit	3763	/	3/	
(use as many s	heets as ne	cessary)	Examiner Name	Unassigned CHUN	CROWDER.	نت	
2	of	2	Attorney Docket Number	018733-1066	ER A 2 TO	Ü	
					· ·	.8	
	INFORMATION STATEMEN	INFORMATION DISCLO STATEMENT BY APPL (use as many sheets as ne	Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) 2 of 2	INFORMATION DISCLOSURE STATEMENT BY APPLICANT Filing Date First Named Inventor Group Art Unit (use as many sheets as necessary) Examiner Name	INFORMATION DISCLOSURE STATEMENT BY APPLICANT Filing Date First Named Inventor Group Art Unit Use as many sheets as necessary Application Number 10/002,211 12/05/2001 12/05/2001 First Named Inventor Group Art Unit 3763 Examiner Name Unassigned-CHUN	INFORMATION DISCLOSURE STATEMENT BY APPLICANT Filing Date First Named Inventor Group Art Unit (use as many sheets as necessary) Application Number 10/002,211 12/05/2001 12/05/2001 First Named Inventor Group Art Unit 3763 Examiner Name Unassigned CHUN CROUPER	

			<u>محر</u>
		NON PATENT LITERATURE DOCUMENTS	
Examiner Initiats*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	-B10	BOSSLET et al., "Immunohistochemical localization and molecular characteristics of three monoclonal antibody-defined epilopes detectable on carcinoembryonic antigen (CEA)," International Journal of Cancer — Journal International Du Cancer, July 15, 1985, pp. 75-84, Vol. 36, No. 1	
	B17	DELAND at al., "Axillary lumphoseintigraphy by radioimmunedataction of carnicombryonic antigen in broast cancer," Journal of Nuclear Medicine, 1979, pp. 1243-1250, Vol. 20, No. 12 Duplicate of IDS filed	126
	_ B18 -	DILHUYDY et al., "Three-dimensional imaging of duel isotope data-sets in a case of acute myocardial infarction." British Journal of Radiology 1992 United Kingdom, March 1992, pp. 273-278, Vol. 65, No. 771	_
	B19	DUNCKER et al., "Radioimmune imaging of bone marrow in patients with suspected bone metastases from primary breast cancer," J. Nucl. Med., 1990, pp. 1450-1455, Vol. 31, No. 9	
	B20	MASUJIMA et al., "Biological component microanalysis by laser photoacoustie imaging immunoassay," Chemical and Pharmaceutical Bulletin (Tokyo), 1989, pp. 1123-1125, Vol. 37, No. 4	
	B21	RESKE et al., "Radioimmunoimaging for diagnosis of bone marrow involvement in breast cancer and malignant lumphoma, " Lancet, 1989, pp. 299-301, Vol. 1, No. 8633	
•	B22	SHARKEY et al., "Murine monoclonal antibodies against carcinoembryonic antigen: immunological, pharmacokinetic and targeting properties in humans," <u>Cancer Research</u> , 1990, pp. 2823-2831, Vol. 50, No. 9	
	B23	SIEGLE et al., "Development of a model using polypeptide anitobodies for scintigraphy of the pancreas," <u>Investigative</u> Radiology, September 1980, pp. 457-461, Vol. 15, No. 5	
	B24	SIGNORE et al., "A radiopharmaceutical for imaging areas of lymphocytic infiltration; lodine-123 interleukin-2: Labelling procedure and animal studies," <u>Nuclear Medicine Communications</u> , October 1992, pp. 713-722, Vol. 13, No. 10	
	B25	SIGNORE et al., "The in vivo visualization of insulitis. A new marker of prediabetes," Advances in Experimental Medicine and Biology, 1988, pp. 119-125, Vol. 246	
-	B26	TAKEDA et al., "Radioimmunolocalization of the monoclonal antibody J28 in-early transformation stages in N-nitrosebis(2-hydroxypropyl)amine-induced pancreatic tumors in the Syrian golden hamster," Journal of Cancer Research and Clinical Oncology, 1992, pp. 377-385, Vol. 118, No. 5	
·	B27	VOLPINI et al., "Diagnosis of acute myocardial infarction by indium-111 antimyosin antibodies and correlation with the traditional techniques for the evaluation of extent and localization," The American Journal of Cardiology, January 1, 1989, pp. 7-13, Vol. 63, No. 1	
		BEST AVAILABLE COPY	

			 	T
Examiner Signature	le-	04	Date Considered	03/01/07

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.